FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.
What happened
FDA inspected the Monterey, CA firm from May 13, 2025, to May 16, 2025. It found the donor questionnaire did not screen for all communicable disease risks and that a directed semen donor who reported a risk factor was determined eligible. FDA also found donor eligibility was documented before test results for Chlamydia trachomatis, Neisseria gonorrhea, and HIV/HCV/HBV NAT were received.
What FDA found
The donor eligibility questionnaire did not ask about all behaviors and conditions that raise the risk of communicable disease, such as certain sexual history, hepatitis, drug use, tattoos/piercings, smallpox vaccination, West Nile virus, and time spent in Europe.
21 CFR 1271.75(a)(1)The firm determined a directed semen donor eligible even though the donor answered yes to having had sex with another man in the preceding five years, a risk factor.
21 CFR 1271.75(d)The firm documented a donor as eligible before receiving results of required communicable disease tests, including Chlamydia trachomatis, Neisseria gonorrhea, and HIV/HCV/HBV NAT.
21 CFR 1271.50(a); 21 CFR 1271.80; 21 CFR 1271.85The firm did not establish and maintain written procedures for all steps in testing, screening, and determining donor eligibility; it said policies were transmitted verbally and the policy book was only for compliance.
21 CFR Part 1271, Subpart C
What FDA wants
FDA tells the firm to respond in writing within 15 working days with specific corrective steps, documentation of corrections, and how it will prevent recurrence. FDA also says affected HCT/Ps must stay in quarantine unless FDA grants an exemption or alternative.
Who should pay attention
- fertility clinics that use donor eggs, sperm, or embryos
- sperm and oocyte banks/donor tissue suppliers
- laboratories and staff performing donor eligibility screening and testing
This is a summary. Read the original letter on fda.gov.